bexarotene has been researched along with Disease Models, Animal in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 10 (20.83) | 29.6817 |
| 2010's | 30 (62.50) | 24.3611 |
| 2020's | 7 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, P; Huang, ZJ; Li, YX; Lin, MH; Lin, QS; Rong, YY; Ye, ZC | 1 |
| Angenendt da Costa, LH; Chang, CF; Massey, J; Osherov, A; Sansing, LH | 1 |
| Ding, Y; Dvornikov, AV; Ekker, SC; Herrmann, J; Hsiai, TK; Kim, M; Lin, X; Lowerison, M; Ma, X; Norton, N; Qiu, Q; Wang, Y; Wang, Z; Xu, X; Yu, Y; Zhang, H; Zhu, P | 1 |
| Dong, H; Wang, H; Wang, L | 1 |
| Aleiwi, B; Carapellucci, S; Ellsworth, E; Krieger-Burke, T; Leal, AS; Liby, KT; Lockwood, B; Moerland, JA; Reich, LA; Zhang, D | 1 |
| Chen, Y; Li, G; Lu, J; Shen, D; Wang, H; Wang, M; Xia, L; Xie, D; Xue, D; Zhang, Y | 1 |
| Casali, BT; Landreth, GE; Reed-Geaghan, EG | 1 |
| Abbasi, M; Chitranshi, N; Chung, R; Dheer, Y; Graham, SL; Gupta, V; Mirzaei, M; You, Y | 1 |
| Liu, D; Qu, X; Tian, JY; Tian, T; Tu, L; Wang, Q; Yang, XL; Zhang, Q | 1 |
| Chen, X; Lee, SB; Lubet, RA; Miller, MS; Mirza, SP; Pan, J; Stevenson, ME; Wang, Y; Xiong, D; You, M; Zhang, Q; Zhou, Y | 1 |
| Mahadevan, L; Michaels, TCT; Weber, CA | 1 |
| Royall, DR | 1 |
| Allard, JS; LaClair, KD; Lee, DL; Manaye, KF; Savonenko, AV; Troncoso, JC; Wong, PC | 1 |
| Burstein, ES; Hubbard, D; Ma, JN; McFarland, K; Olsson, R; Spalding, TA | 1 |
| Bomben, V; Cramer, P; Holth, J; Landreth, G; Noebels, J; Reed, J | 1 |
| Boehm-Cagan, A; Michaelson, DM | 1 |
| Nathans, J; Williams, J; Wu, H | 1 |
| Escudero, P; Ferrando, C; Furio, E; Gonzalez-Navarro, H; Juez, M; Navarro, A; Piqueras, L; Sanz, MJ | 1 |
| Balducci, C; Forloni, G; Grigoli, E; La Vitola, P; Micotti, E; Paladini, A; Richardson, JC; Tolomeo, D | 1 |
| Cao, F; Dong, Z; He, B; Xu, F; Xu, L | 1 |
| Goduni, E; Jay, T; Lamb, BT; Landreth, GE; Malm, T; Mariani, MM; Quigley, C; Ransohoff, RM; Savage, JC | 1 |
| Barbour, B; Guo, JP; Hanna, D; Hobson, P; Jeggo, R; Kim, EM; Lyons, T; McGeer, EG; McGeer, PL; Meara, JR; O'Hare, E; Page, D; Palmer, P; Spanswick, D; Walczak, JS | 1 |
| Fitz, NF; Koldamova, R; Lefterov, I; Mounier, A; Nam, KN; Schug, J | 1 |
| Casali, BT; Corona, AW; Ghosal, K; Karlo, JC; Landreth, GE; Mariani, MM | 1 |
| Casali, BT; Corona, AW; Kodoma, N; Landreth, GE | 1 |
| Bromfield, CR; Burdette, EC; De, AK; Gartia, MR; Ghoshal, G; Misra, SK; Pan, D; Ray, PS; Rund, L; Schook, LB; Schulten, K; Singh, K; Tangella, KV; Williams, EM; Wu, Z; Ye, M | 1 |
| Blanco-Gandía, M; Bonet-Costa, V; Borras, C; Garcia-Tarraga, P; Garcia-Verdugo, JM; Herranz-Pérez, V; Inglés, M; Mas-Bargues, C; Miñarro, J; Rodriguez-Arias, M; Viña, J | 1 |
| Belfort, G; Isaacson, D; Rosenthal, J | 1 |
| Cao, F; Cheng, C; He, J; Huang, Z; Jiang, L; Liu, H; Sun, X; Teng, Z; Wu, J; Wu, Y; Zhang, H; Zhong, J | 1 |
| Chai, DJ; Lin, JX; Lin, LM; Liu, YP; Ning, RB; Peng, F; Xu, CS | 1 |
| Riancho, J | 1 |
| Casali, B; Jay, TR; Lamb, R; Landreth, GE; Malm, T; Mariani, MM; Medarametla, L; Neilson, L | 1 |
| Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y | 1 |
| Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D | 1 |
| Gould, MN; Haag, JD; Sullivan, R; Woditschka, S | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE | 1 |
| Lubet, RA; Wang, Y; Wen, W; Yi, Y; You, M; Zhang, Z | 1 |
| Bagot, M; Bensussan, A; Caudron, A; Marie-Cardine, A | 1 |
| Chang, WC; Clapper, ML; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; McCormick, DL; Pereira, MA; Steele, VE | 1 |
| Brunden, KR; Casali, BT; Cirrito, JR; Cramer, PE; Goebel, WD; James, MJ; Karlo, JC; Landreth, GE; Lee, CY; Restivo, JL; Wesson, DW; Wilson, DA; Zinn, AE | 1 |
| Hull, SC; Lowenthal, J; Pearson, SD | 1 |
| Hede, K | 1 |
| Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z | 1 |
| Brose, HL; Gould, MN; Haag, JD; Hitt, AA; Hu, R; Kim, K; Lindstrom, MJ; Lubet, RA; Mau, B; Monson, DM; Steele, VE; Waller, JL; Watson, PA; Woditschka, S; Zheng, Y | 1 |
| Bultel, S; Fiévet, C; Fruchart, JC; Kuipers, F; Lalloyer, F; Lestavel, S; Paumelle, R; Staels, B; Tailleux, A; Torpier, G; Touche, V; van der Veen, J; Yous, S | 1 |
| Budel, V; Cahen, P; Chaboteaux, C; Darro, F; Decaestecker, C; Kiss, R; Leblond, B; Nogaret, JM; Pétein, M; Pourrias, B; Ramos, C; Schoofs, A; Vianna, A | 1 |
| Brown, PH; Green, JE; Hilsenbeck, SG; Kim, HT; Kuhn, JG; Lamph, WW; Mohsin, SK; Rodriquez, JL; Wu, K; Xu, XC | 1 |
1 review(s) available for bexarotene and Disease Models, Animal
| Article | Year |
|---|---|
[New developments in Sézary syndrome].
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Combined Modality Therapy; Diphtheria Toxin; Disease Models, Animal; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Interleukin-2; Mice; Mice, SCID; Molecular Targeted Therapy; Photopheresis; PUVA Therapy; Receptors, KIR3DL2; Recombinant Fusion Proteins; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Therapies, Investigational | 2012 |
47 other study(ies) available for bexarotene and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Bexarotene enhances astrocyte phagocytosis via ABCA1-mediated pathways in a mouse model of subarachnoid hemorrhage.
Topics: Animals; Astrocytes; ATP Binding Cassette Transporter 1; Benzoates; Bexarotene; Biphenyl Compounds; Disease Models, Animal; Membrane Proteins; Mice; Phagocytosis; Retinoid X Receptors; Subarachnoid Hemorrhage | 2022 |
Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage.
Topics: Animals; Bexarotene; Brain; Cerebral Hemorrhage; Disease Models, Animal; Erythrocytes; Hematoma; Macrophages; Microglia; Phagocytosis | 2020 |
Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity.
Topics: Animals; Bexarotene; Cardiotonic Agents; Cardiotoxicity; Disease Models, Animal; Endothelial Cells; Heart; Humans; Isotretinoin; Myocardium; Neoplasms; Pericardium; Retinoid X Receptor alpha; Zebrafish; Zonula Occludens-1 Protein | 2020 |
Inhibition of MAPT enhances the effect of bexarotene and attenuates the damage after traumatic brain injury using in vivo and in vitro experiments.
Topics: Animals; Apoptosis; Bexarotene; Brain; Brain Injuries, Traumatic; Cell Proliferation; Disease Models, Animal; HEK293 Cells; Humans; Mice; Neuroprotective Agents; Oxidative Stress; Signal Transduction; tau Proteins | 2020 |
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Carcinogens; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Immunohistochemistry; Immunomodulation; Lung Neoplasms; Mice; Molecular Structure; Proto-Oncogene Proteins p21(ras); Retinoid X Receptors; Sterol Regulatory Element Binding Proteins; Tetrahydronaphthalenes; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Bexarotene; Binding Sites; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Gene Expression; Humans; Mice; Models, Molecular; Molecular Conformation; Nuclear Receptor Subfamily 2, Group C, Member 2; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Protein Binding; Protein Transport; Signal Transduction; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2021 |
Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Bexarotene; Cells, Cultured; Cognition; Cognition Disorders; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Transgenic; Peptide Fragments; Plaque, Amyloid; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors | 2018 |
Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; bcl-Associated Death Protein; Bexarotene; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Endoplasmic Reticulum Stress; Humans; Male; Mice, Inbred C57BL; Neuroprotection; Neurotoxicity Syndromes; Receptor, trkB; Retinoid X Receptors; Up-Regulation | 2018 |
Bexarotene attenuates early brain injury via inhibiting micoglia activation through PPARγ after experimental subarachnoid hemorrhage.
Topics: Animals; Bexarotene; Brain; Cell Death; Cytokines; Disease Models, Animal; Inflammation; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; PPAR gamma; RNA, Messenger; Subarachnoid Hemorrhage; Tetrahydronaphthalenes | 2018 |
Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice.
Topics: Adenocarcinoma of Lung; Administration, Oral; Aerosols; Animals; Anticarcinogenic Agents; Bexarotene; Carcinoma, Squamous Cell; Disease Models, Animal; Drug Compounding; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Lung; Lymphocytes, Tumor-Infiltrating; Mice; Signal Transduction | 2019 |
Optimal control strategies for inhibition of protein aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; Caenorhabditis elegans; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Kinetics; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Time Factors | 2019 |
The "ethics" of evidence are not evidence of ethics.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Ethics, Medical; Humans; Off-Label Use; Tetrahydronaphthalenes; United States | 2013 |
Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Behavior, Animal; Bexarotene; Blotting, Western; Disease Models, Animal; Female; Male; Memory; Mice; Mice, Mutant Strains; Plaque, Amyloid; Tetrahydronaphthalenes | 2013 |
Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.
Topics: Administration, Oral; Animals; Behavior, Animal; Bexarotene; Bioluminescence Resonance Energy Transfer Techniques; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Infusions, Subcutaneous; Injections, Intraventricular; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Primary Cell Culture; Protein Multimerization; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 2013 |
Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; Cerebral Cortex; Cognition; Disease Models, Animal; Electroencephalography; Epilepsy; Hippocampus; Memory; Mice; Retinoid X Receptors; Tetrahydronaphthalenes | 2014 |
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Topics: Amyloid beta-Peptides; Animals; Anticarcinogenic Agents; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Bexarotene; Brain; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Lipoproteins; Maze Learning; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments; Recognition, Psychology; Tetrahydronaphthalenes; Time Factors | 2014 |
Complete morphologies of basal forebrain cholinergic neurons in the mouse.
Topics: Alkaline Phosphatase; Alzheimer Disease; Animals; Axons; Basal Forebrain; Bexarotene; Cell Line; Cholinergic Neurons; Disease Models, Animal; Disease Progression; Hippocampus; Image Processing, Computer-Assisted; Mice; Mice, Knockout; Microscopy, Confocal; Tetrahydronaphthalenes | 2014 |
Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Bexarotene; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Rosuvastatin Calcium; Signal Transduction; Tetrahydronaphthalenes | 2015 |
The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Bexarotene; Brain; Disease Models, Animal; Female; Liver X Receptors; Maze Learning; Mice; Mice, Transgenic; Microglia; Orphan Nuclear Receptors; Retinoid X Receptors; Tetrahydronaphthalenes; Treatment Failure | 2015 |
Bexarotene reduces blood-brain barrier permeability in cerebral ischemia-reperfusion injured rats.
Topics: Animals; Apolipoproteins E; Bexarotene; Blood-Brain Barrier; Brain Ischemia; Claudin-5; Disease Models, Animal; Gene Expression Regulation; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; Occludin; Rats; Tetrahydronaphthalenes | 2015 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer Tyrosine Kinase; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Leukocyte Common Antigens; Macrophages; Male; Membrane Glycoproteins; Mice; Microglia; Myeloid Cells; Phagocytosis; Pioglitazone; Plaque, Amyloid; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones | 2015 |
Lack of support for bexarotene as a treatment for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; CA1 Region, Hippocampal; CHO Cells; Conditioning, Operant; Cricetulus; Culture Media, Conditioned; Disease Models, Animal; Excitatory Postsynaptic Potentials; Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Transgenic; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 2016 |
RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
Topics: Adaptor Proteins, Signal Transducing; Amyloid beta-Peptides; Animals; Anticarcinogenic Agents; Apolipoproteins E; Bexarotene; Brain; Disease Models, Animal; Gene Expression Regulation; Membrane Glycoproteins; Mice; Mice, Transgenic; Phagocytosis; Receptors, Immunologic; Retinoid X Receptors; Sequence Analysis, RNA; Tetrahydronaphthalenes; Up-Regulation | 2015 |
Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Bexarotene; Brain; Cells, Cultured; Disease Models, Animal; Docosahexaenoic Acids; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Tetrahydronaphthalenes | 2015 |
ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; Bexarotene; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hippocampus; Humans; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Polymerase Chain Reaction; Presenilin-1; Tetrahydronaphthalenes | 2016 |
Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for Treating Liver Cancer.
Topics: Animals; Bexarotene; Catheters; Combined Modality Therapy; Disease Models, Animal; Drug Repositioning; Electricity; Electrophoresis; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Hyperthermia, Induced; Liver Neoplasms; Molecular Dynamics Simulation; Nanoparticles; Prodrugs; Quantum Theory; Retinoid X Receptor alpha; Spectrum Analysis, Raman; Sus scrofa; Tetrahydronaphthalenes; Thermodynamics; Ultrasonics; Ultrasonography | 2015 |
Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Astrocytes; Avoidance Learning; Bexarotene; Brain; Cells, Cultured; Disease Models, Animal; Female; Genistein; Habituation, Psychophysiologic; Maze Learning; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Nootropic Agents; Olfactory Perception; Plaque, Amyloid; PPAR gamma; Recognition, Psychology; Tetrahydronaphthalenes | 2016 |
Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticarcinogenic Agents; Bexarotene; Brain; Computer Simulation; Disease Models, Animal; Mice; Models, Theoretical; Tetrahydronaphthalenes | 2016 |
Bexarotene protects against traumatic brain injury in mice partially through apolipoprotein E.
Topics: Animals; Apolipoproteins E; Apoptosis; Bexarotene; Brain; Brain Injuries, Traumatic; Caspase 3; Disease Models, Animal; Male; Mice, Inbred C57BL; Mice, Knockout; Microglia; Motor Activity; Neuroprotective Agents; Random Allocation; Spatial Memory; Tetrahydronaphthalenes | 2017 |
Coadministration of VDR and RXR agonists synergistically alleviates atherosclerosis through inhibition of oxidative stress: An in vivo and in vitro study.
Topics: Animals; Aorta, Thoracic; Apoptosis; Atherosclerosis; Bexarotene; Diabetes Complications; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Interleukin-10; Interleukin-6; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Protein Kinase C; Reactive Oxygen Species; Receptors, Calcitriol; Retinoid X Receptors; RNA, Small Interfering; Superoxide Dismutase; Tetrahydronaphthalenes | 2016 |
Retinoids and PPAR agonists: Promising partners in neurodegenerative diseases?
Topics: Animals; Bexarotene; Disease Models, Animal; Gene Expression Regulation; Humans; Mice; Neurodegenerative Diseases; Neuroprotective Agents; PPAR gamma; Receptors, Retinoic Acid; Retinoid X Receptors; Tetrahydronaphthalenes; Vitamin A | 2016 |
Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Bexarotene; Biomarkers; Cell Survival; Cytokines; Disease Models, Animal; Female; Gliosis; Glutamic Acid; Habituation, Psychophysiologic; Hippocampus; Inflammation; Male; Membrane Transport Proteins; Memory; Mice, Transgenic; Neurons; Neurotoxins; Olfactory Bulb; Plaque, Amyloid; Receptors, LDL; Retinoid X Receptors; Synapses; Tetrahydronaphthalenes | 2017 |
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53 | 2009 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53 | 2009 |
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma in Situ; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Pyrazoles; Rats; Rats, Inbred WF; Retroviridae; Sulfonamides; Tamoxifen; Tetrahydronaphthalenes; Time Factors | 2009 |
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.
Topics: Adenoviridae; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Apoptosis; Bexarotene; Budesonide; Cell Proliferation; Disease Models, Animal; Female; Genetic Engineering; Immunoenzyme Techniques; In Situ Nick-End Labeling; Integrases; Lung Neoplasms; Male; Mice; Mice, Inbred A; Retinoblastoma Protein; Small Cell Lung Carcinoma; Tetrahydronaphthalenes; Tumor Suppressor Protein p53 | 2009 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Head and Neck Neoplasms; Intestinal Neoplasms; Male; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Neoplasms; Pyrazoles; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sulfonamides; Tetrahydronaphthalenes; Urinary Bladder Neoplasms | 2012 |
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Apolipoproteins E; Astrocytes; Behavior, Animal; Bexarotene; Brain; Disease Models, Animal; Extracellular Fluid; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Molecular Targeted Therapy; Odorants; Olfactory Pathways; Orphan Nuclear Receptors; Phagocytosis; Plaque, Amyloid; PPAR gamma; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Ethics, Medical; Humans; Mice; Off-Label Use; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2012 |
Rexinoids may be ready for prime time in prevention, but challenges remain.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Nicotinic Acids; Piperidines; Retinoid X Receptors; Tetrahydronaphthalenes; Thiophenes | 2004 |
Prevention of lung cancer progression by bexarotene in mouse models.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Bexarotene; Carcinogens; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Urethane | 2006 |
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Body Weight; Disease Models, Animal; Female; Genes, erbB-2; Genetic Vectors; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Nicotinic Acids; Rats; Rats, Inbred WF; Retroviridae; Tamoxifen; Tetrahydronaphthalenes | 2006 |
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Bexarotene; CD13 Antigens; Cholesterol; Disease Models, Animal; Dyslipidemias; Female; Gene Expression Regulation; Homeostasis; Intestinal Absorption; Lipoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Retinoid X Receptors; Tetrahydronaphthalenes; Triglycerides | 2006 |
Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
Topics: Alitretinoin; Animals; Anticarcinogenic Agents; Apoptosis; Benzoates; Bexarotene; Breast Neoplasms; Cell Division; Disease Models, Animal; Female; Fenretinide; Hormone Antagonists; Humans; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mifepristone; Retinoids; Tamoxifen; Tetrahydronaphthalenes; Tretinoin; Tumor Cells, Cultured | 1998 |
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Benzoates; Bexarotene; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Growth Inhibitors; Histones; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Sensitivity and Specificity; Tetrahydronaphthalenes; Time Factors; Transcription Factors; Treatment Outcome | 2002 |